{"id":833983,"date":"2025-04-04T08:37:55","date_gmt":"2025-04-04T12:37:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/"},"modified":"2025-04-04T08:37:55","modified_gmt":"2025-04-04T12:37:55","slug":"palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/","title":{"rendered":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WAYNE, Pa., April  04, 2025  (GLOBE NEWSWIRE) &#8212; (Nasdaq: PVLA) <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fQ_sdhLMuIPRbC6Spkxe9E_32hqaw_S0na0ZM8eMEX1WHfHVFIFuBarZutzXgMbr42peSU-dHM_IWwTjFqy74EpxP_JWK17CTrP1Q3iGZcY=\" rel=\"nofollow\" target=\"_blank\">Palvella Therapeutics, Inc.<\/a> (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of\u00a0Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT.<\/p>\n<p align=\"justify\">A live webcast of the fireside chat will be available on the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RHLmfAroc8M-2qWs2NLRLIBLXQXyhn_KGJQd-1zv0dgDcR_KZopyR5RTmWn_VvkCcrHy01tG-cj7pv1u5ib6hUfH065vJ-MEP3FhOFVNkaNTEC-m2Jbp7P3v3TNVvrk2xuBPO_Ht-ywjkgOSUL7uNw==\" rel=\"nofollow\" target=\"_blank\">Events and Presentations<\/a>\u00a0section of Palvella&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ucykMBIK51QB19Eme_2LggnBuFA_xFwAtU6RYqheAPUZsmkShZSl5y8SA8GUy9G-rDhblAPvbP9C9DvsASstL_kcL40wq_ryGk6XXG8G17A=\" rel=\"nofollow\" target=\"_blank\">www.palvellatx.com<\/a>. An archived replay of the webcast will be available for approximately 90 days following the presentation.<\/p>\n<p>\n        <strong>About Palvella Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN\u2122 platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella\u2019s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN\u2122 rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ucykMBIK51QB19Eme_2LggjCK2DVvvf0piLFlzjRprLhUU99vwYvvF_UD6Vt0geGwq7G64iGyrrfCh0yCpBSNy7XbD91KJIFWaERDgGerRA=\" rel=\"nofollow\" target=\"_blank\">www.palvellatx.com<\/a> or follow Palvella on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JVjk9CO5Iu1XS_UQiSWwsdX-Xn_kRauZvLnT2QAEDM8tvbzG-0XHPts8YHWQULAMOSsCTm6WzxauG9hbcM9yD2Tf-jnBs4SVpD_oRm-hhIPlSvyiufpjmWDNG1XqMZ4Co7oSMsyrLy1EYDtnb2Ez3zSzwFD7W7A51zSLAAjqYRlR5nMEt15invO012fQxzgJXj6w1emmWzvoN-GRTlH3-fqwB5PPBJu-B39_1fGaJxeFeNVMWudgx05YNYPiZWkcRFBPeeNdfgKcDycbWP0-f40Z_khnMNUXdUvPEs1voONSwGS29hGFSTYPzCns1eYjfF5gLNt2Bv2IsDpqoXC53ZzGhJIn7TZCN6HaM-URpIQPgX1RCgZ9GU4E_9Z6Epcgs2g2PWdW1yQA80p5dWhK60VruyuBA2tke1IPDehwjdY=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wpao1ZToZNwERHC5zG3Q4yNVeWJIsq_hJdJYTRH0SnZbCj6zDrToh37bcz2XW06f3Rhf29naE5NSTdailYGkyA==\" rel=\"nofollow\" target=\"_blank\">X<\/a> (formerly known as Twitter).<\/p>\n<p align=\"justify\">QTORIN\u2122 rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.<\/p>\n<p>\n        <strong>Contact\u00a0Information<\/strong>\n      <\/p>\n<p>\n        <u>Investors<\/u><br \/>\n        <br \/>Wesley H. Kaupinen<br \/>Founder and CEO, Palvella Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DuHXi_fnL-IDjZCKs7HFTmE36EhTiNRdHMMCIykVlpwm1dMKyORHxMuEWCnQ2nkvJKbV0Df4cu4Xh9L2YLBt5J5DgYBRPZY3VZdJrhsv21sGMTZUYA9_L6tRfM-fCepE\" rel=\"nofollow\" target=\"_blank\">wes.kaupinen@palvellatx.com<\/a><\/p>\n<p>\n        <u>Media<\/u><br \/>\n        <br \/>Marcy Nanus<br \/>Managing Partner, Trilon Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F6B4A5TTcNN1u1o8U7NM5KqCCRMV4krpOHnpU7Y4rVqwWDEe5yblIPnAPIfdAcPNUOrw3amwDBhaCgD5KUHAtA3x-jdj7mMToxlzwH3NBdueoh8lLxxsegFJv3xqkKtm\" rel=\"nofollow\" target=\"_blank\">mnanus@trilonadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjZiNjIyZjktOGUyZC00ZmI1LThlMjYtODliODgxZDRmYWM5LTExMzQ3MzQtMjAyNS0wNC0wNC1lbg==\/tiny\/Palvella-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) &#8212; (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of\u00a0Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT. A live webcast of the fireside chat will be available on the\u00a0Events and Presentations\u00a0section of Palvella&#8217;s website at\u00a0www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-833983","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) &#8212; (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of\u00a0Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT. A live webcast of the fireside chat will be available on the\u00a0Events and Presentations\u00a0section of Palvella&#8217;s website at\u00a0www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led &hellip; Continue reading &quot;Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-04T12:37:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference\",\"datePublished\":\"2025-04-04T12:37:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/\"},\"wordCount\":310,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/\",\"name\":\"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=\",\"datePublished\":\"2025-04-04T12:37:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - Market Newsdesk","og_description":"WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) &#8212; (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of\u00a0Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT. A live webcast of the fireside chat will be available on the\u00a0Events and Presentations\u00a0section of Palvella&#8217;s website at\u00a0www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led &hellip; Continue reading \"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-04T12:37:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference","datePublished":"2025-04-04T12:37:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/"},"wordCount":310,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/","name":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=","datePublished":"2025-04-04T12:37:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzA0MiM2ODUxMzY4IzIxMjMxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=833983"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833983\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=833983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=833983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=833983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}